Literature DB >> 17916554

Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E.

Menachem J Gunzburg1, Matthew A Perugini, Geoffrey J Howlett.   

Abstract

Apolipoprotein (apo) E is a well characterized lipid-binding protein in plasma that also exists as a common nonfibrillar component of both cerebral and systemic amyloid deposits. A genetic link between a common isoform of apoE, apoE4, and the incidence of late onset Alzheimer disease has drawn considerable attention to the potential roles of apoE in amyloid-related disease. We examined the interactions of apoE with amyloid fibrils composed of apoC-II and the amyloid-beta (Abeta) peptide. Aggregates of apoE with Abeta and apoC-II are found in Alzheimer and atherosclerotic plaques, respectively. Sedimentation velocity and fibril size distribution analysis showed that apoE3 and E4 isoforms bind and noncovalently cross-link apoC-II fibrils in a similar manner. This ability to cross-link apoC-II fibrils was abolished by the dissociation of the apoE tetramer to monomers or by thrombin cleavage to yield separate N- and C-terminal domains. Preparative ultracentrifuge binding studies indicated that apoE and the isolated N- and C-terminal domains of apoE bind with submicromolar affinities to both apoC-II and Abeta fibrils. Fluorescence quenching and resonance energy transfer experiments confirmed that both domains of apoE interact with apoC-II fibrils and demonstrated that the binding of the isolated N-terminal domain of apoE to apoC-II or Abeta fibrils is accompanied by a significant conformational change with helix three of the domain moving relative to helix one. We propose a model involving the interaction of apoE with patterns of aligned residues that could explain the general ability of apoE to bind to a diverse range of amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916554     DOI: 10.1074/jbc.M706425200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  An equilibrium model for linear and closed-loop amyloid fibril formation.

Authors:  Shuo Yang; Michael D W Griffin; Katrina J Binger; Peter Schuck; Geoffrey J Howlett
Journal:  J Mol Biol       Date:  2012-02-24       Impact factor: 5.469

Review 2.  Apolipoproteins and amyloid fibril formation in atherosclerosis.

Authors:  Chai Lean Teoh; Michael D W Griffin; Geoffrey J Howlett
Journal:  Protein Cell       Date:  2011-03-12       Impact factor: 14.870

3.  In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: misfolding induced by frustration of the salt bridge network.

Authors:  Jinghui Luo; Jean-Didier Maréchal; Sebastian Wärmländer; Astrid Gräslund; Alex Perálvarez-Marín
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

4.  Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Authors:  Richard J Perrin; Rebecca Craig-Schapiro; James P Malone; Aarti R Shah; Petra Gilmore; Alan E Davis; Catherine M Roe; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Jeffrey A Kaye; John C Morris; David M Holtzman; R Reid Townsend; Anne M Fagan
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

5.  Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Alexander Vezeridis; Vassilis I Zannis; Efstratios Stratikos
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 6.  Basic mechanisms of neurodegeneration: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

Review 7.  Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis.

Authors:  Yun Chen; Michael R Strickland; Andrea Soranno; David M Holtzman
Journal:  Neuron       Date:  2020-11-10       Impact factor: 17.173

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.